Copyright
©The Author(s) 2023.
World J Crit Care Med. Jan 9, 2023; 12(1): 18-28
Published online Jan 9, 2023. doi: 10.5492/wjccm.v12.i1.18
Published online Jan 9, 2023. doi: 10.5492/wjccm.v12.i1.18
Table 1 Trial characteristics
| Ref. | Type of study | Study dates | Total patients studied | ICU | Admitting diagnosis | Mechanical ventilation | Age (yr) | Sex | Weight (kg) | BMI (kg/m2) | APACHE score |
| Terry et al[24], 2015 | Single-center, retrospective, observational study | February 1, 2013-February 28, 2014 | 26 | Cardiac surgery 21 (80.7%), thoracic 3 (11.5%), neurology 1 (3.8%), surgical 1 (3.8%) | Respiratory 4 (15.4%), cardiac 20 (76.9%), trauma 1 (3.8%), substance abuse 1 (3.8%) | 4 (14.8%) | 54.4 ± 16.91 | Male: 17 (63%), female: 9 (37%) | NR | 32 ± 3.11 | 18 (14-22)2 |
| Gagnon et al[23], 2015 | Single-center prospective observational pilot study | January, 2014-March, 2014 | 20 | Mixed medical, surgical, neuro ICU | Respiratory 12 (60%), neurologic 1 (5%), trauma 2 (10%), substance abuse 2 (10%), other 3 (15%) | 13 (65%) | 62 (54-73)2 | Male: 13 (65%), female: 7 (35%) | NR | 29.9 (26.5-33.1)2 | 62 (54-80)2 |
| Bhatt et al[22], 2020 | Single-center, prospective, double cohort observational study | November, 2017-December, 2018 | 42 | Medical-surgical 10 (67%) vs 13 (48%), cardiothoracic 3 (20%) vs 8 (30%), neurosurgical 2 (13%) vs 6 (22%) | Respiratory 16 (38.1%), cardiac 12 (28.6%), gastroenterological 5 (11.9%), neurologic 2 (4.8%), trauma 1 (2.4%), sepsis/shock 6 (14.3%) | NR | Clonidine taper: 58 (43-662 vs no taper: 54 (45-66)2 | Male: 27 (64%), female: 15 (36%) | Clonidine taper: 86.9 (67.3-94.1)2 vs no taper 91.6 (78.9-101.1)2 (P = 0.19) | NR | NR |
- Citation: Rajendraprasad S, Wheeler M, Wieruszewski E, Gottwald J, Wallace LA, Gerberi D, Wieruszewski PM, Smischney NJ. Clonidine use during dexmedetomidine weaning: A systematic review. World J Crit Care Med 2023; 12(1): 18-28
- URL: https://www.wjgnet.com/2220-3141/full/v12/i1/18.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v12.i1.18